The IT @ Networking Awards 2010 - Open Competition for Healthcare IT Solutions

The IT @ Networking Awards 2010 (IT @ 2010) is an open competition for fully implemented, operable healthcare IT solutions. The goal is to raise awareness of some of the world's finest and most innovative local, regional and national healthcare IT projects.

Recognition
High-tech, high-cost medicine; ageing populations; patient mobility and staff shortages are only some of the challenges healthcare providers face today. Intelligent IT solutions increase cost-effectiveness, productivity and safety and help healthcare facilities to confront these problems. IT @ 2010 brings these innovations into the global spotlight and provides them with the recognition and media attention they deserve.

Their stories will inspire others, proving that challenges can be transformed into future opportunities and success stories.

Novel and Interactive
The core aim of IT @ 2010 is to learn from the mistakes and achievements of different top IT installations. Our unique peer-to-peer voting system empowers daily users such as CEOs, CIOs, CMIOs, hospital and IT managers to vote for their preferred projects, as they are best placed to judge the real value of projects.

First Day - MindByte Session
All Nominees will present in the MindByte, a five minute introductory presentation followed by a lively five minute Q&A. The qualifying audience will vote immediately after each presentation according to the voting criteria for their favourite solution.

Becoming a Nominee is a huge achievement and each will be awarded the prestigious IT @ 2010 Nominee Silver Medal.

Second Day - WorkBench Session
The nine top-rated Nominees will progress as Finalists into the next day WorkBench, a 30-minute in-depth presentation followed by a 15 minute Q&A discussion, providing the audience with a thorough understanding of the project. The qualifying audience will vote immediately after each presentation to choose the winners. Finalists will be awarded the prestigious IT @ 2010 Finalist Gold Medal.

The Prize
The top three IT solutions will be awarded a prize.

THE WINNING PROJECT WILL RECEIVE:
The IT @ Networking Awards 2010 Trophy;
A cash prize of € 5,000;
Media promotion in Europe's leading healthcare management media worth € 50,000.

THE 2ND PROJECT WILL RECEIVE:
The IT @ Networking Awards 2010 Trophy;
Media promotion in Europe's leading healthcare management media worth € 25,000.

THE 3RD PROJECT WILL RECEIVE:
The IT @ Networking Awards 2010 Trophy.

How to submit your project?
All entries must already be implemented in at least one site and must be fully operable. All projects must be presented in accordance to the voting criteria. The maximum length of the abstract is 300 words.

For your chance to win, please enter your submission through www.conftool.com/itawards2010

Submission deadline for the Abstract is 25 June 2010.

All project submissions (Abstracts) will be presented to the IT @ 2010 Review Committee. This Review Committee will decide the top 25 IT solutions that will become Nominees and will take part in the MindByte Session.

Submissions without any commercial interest or any link to healthcare service providers are free. All the others are charged a one time registration fee of 1000 EUR.

All nominees are required to submit a 5 minute PowerPoint or Keynote presentation for the first MindByte Session. This is your chance to explain to the audience what differentiates your solution and what makes it special.

Submission deadline for the MindByte Presentation is 31 August 2010.

As a nominee you are also required to submit a 30-minute presentation for the second day WorkBench Session.

Submission deadline for the Workbench Presentation is 20 September 2010.

For further information and registration, please visit:
http://itandnetworking.org

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Roche's personalised medicine entrectinib shrank t…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adole...